Objective: To assess quality of life in multiple sclerosis (MS) patients and determine the factors associated with levels of quality of life in MS patients in a public hospital in Saudi Arabia.

Methods: A cross-sectional study was conducted from June 2016 to April 2017 in King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia. Multiple sclerosis patients attending the outpatient and inpatient services were approached and recruited to participate in the study. The Arabic version of EuroQOL-5 Dimensions instrument (EQ-5D) was utilized for the assessment of MS patients quality of life.

Results: Data on quality of life were obtained from 292 patients. The reported quality of life of MS patients was as measured by the EQ-5D index value score was 0.31±0.51 and the EQ-VAS score was 73.87±23.41, respectively. It was found that quality of life determined numerically in the EQ-5D index value and EQ-VAS deteriorates proportionally according to the disease duration.

Conclusion: Multiple sclerosis is associated with a considerable effect on the patients quality of life. It continues to be challenging to manage both medically and psychosocially. Clinicians should consider the assessment of quality of life as routine practice along with the other important measures including symptomatic evaluation, laboratory tests, and neuroimaging to provide a holistic care of their MS patients.
Quality of Life among MS Patients … Algahtani et al

250/100,000 with approximately 2.5 million total cases affected worldwide. Clinically, MS patients experience recurrent episodes of neurological impairment (relapses), and the disease becomes chronic and progressive with time, which subsequently leads to motor disability and cognitive deficits. Assessment of quality of life is one of the most important methods to measure the impact of the disease on the patient. It also helps to monitor the clinical status of the patients and to measure the treatment efficacy. In this study, we aim to assess quality of life in MS patients and determine the factors associated with levels of quality of life in MS patients in a public hospital in Saudi Arabia. The results obtained will help to improve healthcare for MS patients and assess the social impact and economic cost of this disease by indicating their specific needs for pharmacotherapy, rehabilitation, and multidisciplinary care.

Methods. This is a cross-sectional study carried out in King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia. Data collection started from June 2016 to April 2017. Patients who have MS and attending the inpatient and outpatient services were asked to participate in the study. From a total of 352 MS patients, 292 (82.95%) participated in the study. Face to face interview was conducted by the neurology consultants to assure the credibility of the interview process and correctness of the collected data. Collected data from all MS patients includes their demographic profile (i.e. age and gender), illness information (i.e. form of MS, age at disease onset, duration of illness, and current treatment), and health status by utilizing the EuroQOL-5 Dimensions (EQ-5D) questionnaire in Arabic version.

The validity and reliability of the Arabic version of the EQ-5D questionnaire have been demonstrated for the general Arabian population. The EQ-5D is a generic instrument that has been widely used for generalizability and comparability on patients’ general well-being and ability to function in everyday life. This is comprised of 2 parts; the first part is the EQ-5D descriptive system that involved patient self-reporting of their health status in terms of 5 dimensions: mobility, self-care, usual activates, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. Since the numerals 1-5 have no arithmetic properties and cannot be used as a cardinal score, the EQ-5D index value for MS patients quality of life was calculated based on United Kingdom (UK) value set in Crosswalk Index Value Calculator. The second part is the EuroQol Visual Analog Scale (EQ-VAS), which is a 20 cm visual vertical scale labeled “the best health you can imagine=100” and “the worst health you can imagine=0” to rate themselves about their current health status. The EQ-VAS, however, does not influence the EQ-5D-5L index but provides an additional information about their quality of life. This study was registered with EuroQol, and permission was given for its use (ID: 7305, approval date: 5 December 2014).

Descriptive statistics such as frequency, percentage, mean and standard deviation (SD) were used to describe and synthesize MS patients’ demographic data, illness information, and reported problems for each level for each dimension of EQ-5D. Inferential statistics were then applied to determine differences in MS patients’ EQ-5D index value when grouped according to demographic variables (i.e. gender) and illness information (i.e. duration of illness). Independent t-test was utilized to test the significance of differences between nominal variables (i.e. gender) and one-way ANOVA to test significant differences between more than 2 groups in interval data (i.e. duration of illness). The Pearson correlation coefficient was used to assess the correlation between the reported EQ-VAS scores and EQ-5D-5L index values. Multiple linear regression was carried out to identify which variables were significantly associated with the quality of life of MS patients (dependent variable). The independent variables were age, sex, duration of illness, and on treatment or not on treatment. The Statistical Package for Social Sciences (SPSS) version 21.0 was used for data analysis. The significance level was predetermined at p-level<0.05 for all tests.

All questionnaires were anonymous, and confidentiality of information was ensured. Instructions to complete the questionnaire and confidentiality issues were explained on the cover page of each questionnaire. Completion of the questionnaire was considered as a consent to participate in the study. This study was approved by the Institutional Review Board (IRB) of King Abdullah International Medical Research Center (KAIMRC).

Results. Data on quality of life were obtained from 292 patients. Total mean age for the entire group of patients was 35.95±10.26 years (range 14-70 years), with a mean age of the women being 35.96±10.59 years and mean age of the men 35.94±9.53 years. Females

Disclosure. The authors declare no conflicting interests, support or funding from any drug company.
represented 69.2% of the study population (202 patients), with males represented 30.8% (90 patients), with a gender ratio of 2.24:1. The mean age at onset of the disease was 28.43±9.42 years old; range 11-63 years. The mean duration of the disease was 7.63±6.17 years; ranging from 2 weeks to 35 years. Detailed patients' demographic data are presented in Table 1.

Most of our patients included in the study 259 (88.7%) had a relapsing-remitting form of the disease, 12 (4.1%) were secondary progressive, and 21 (7.2%) were primary progressive. Most of the patients 244 (83.6%) were receiving disease modifying drugs and 48 (16.4%) were not on treatment.

The results of the subjective assessment of the EQ-5D are shown in Figure 1. The EQ-5D index was 0.27±0.51 for the females, while it was 0.40±0.50 for the males. The EQ-5D index for all patients was 0.31±0.51. No significant difference was found between genders (p=0.6). It was found that quality of life numerically in the EQ-5D deteriorates proportionally according to the duration of the disease (Figure 2).

The reported quality of life of MS patients as measured by the EQ-5D index value was 0.31±0.51 and the EQ-VAS score was 73.87±23.41. The distribution of reported no problems across dimensions of quality of life was as follows: mobility 79 (27.1%), usual activities 93 (31.8%), self-care 116 (39.7%), pain/discomfort 82 (28.1%), and anxiety/depression 77 (26.4%) (Table 2). A total of 178 states of health were reported by the participants. We found that 25 (8.6%) patients reported no problems for any dimension and 14 (4.8%) patients reported extreme problems in all 5 dimensions. The mean score of the EQ-VAS for the females was 73.24±22.52, while it was 75.28±25.38 for the males.

### Table 1 - Baseline demographics of multiple sclerosis patients

| Demographics               | Women     | Men       | All Patients |
|----------------------------|-----------|-----------|--------------|
| Patients n (%)             | 202 (69.2) | 90 (30.8) | 292          |
| Women vs Men               | -         | -         | 2.24:1 ratio |
| Age (years)                | 35.96 ±10.59 | 35.94 ±9.53 | 35.95±10.26 |
| Age at disease onset       | 28.33 ±9.69 | 28.66 ±8.83 | 28.43±9.42 |
| Duration of illness (years)| 7.68±6.31 | 7.52±5.88 | 7.63±6.17    |
| Forms of multiple sclerosis n (%) |           |           |              |
| RRMS                       | 78 (26.7) | 181 (62) | 259 (88.7)   |
| SPMS                       | 6 (2.05)  | 6 (2.05) | 12 (4.1)     |
| PPMS                       | 6 (2.05)  | 15 (5.1) | 21 (7.2)     |
| EQ-5D index                | 0.27 (0.51) | 0.40 (0.50) | 0.31 (0.51) |
| EQ-VAS                     | 73.24 (22.52) | 75.28 (25.38) | 73.87(23.41) |

SD - standard deviation PRMS - Progressive-relapsing MS, SPMS - secondary progressive MS, PPMS - primary progressive MS, EQ-5D - EuroQOL-5 Dimensions instrument

![Image of EQ-5D Dimensions instrument]

**Figure 1** - Subjective assessment of EQ-5D dimensions instrument.

### Table 2 - Frequency distribution of MS patients reporting levels 1 to 5 by dimensions and by age group.

| EQ-5D dimensions | 14-20 | 21-30 | 31-40 | 41-50 | 51-60 | 61-70 | Total |
|------------------|-------|-------|-------|-------|-------|-------|-------|
| Mobility level   |       |       |       |       |       |       |       |
| 1                | 8     | 23    | 25    | 14    | 9     | 0     | 79    |
| 2                | 0     | 9     | 25    | 19    | 1     | 1     | 55    |
| 3                | 1     | 15    | 19    | 13    | 2     | 3     | 53    |
| 4                | 0     | 6     | 15    | 8     | 2     | 0     | 31    |
| 5                | 2     | 29    | 24    | 12    | 5     | 2     | 74    |
| Self-Care level  |       |       |       |       |       |       |       |
| 1                | 8     | 31    | 43    | 23    | 10    | 1     | 116   |
| 2                | 0     | 4     | 13    | 9     | 0     | 0     | 26    |
| 3                | 0     | 7     | 9     | 7     | 1     | 0     | 24    |
| 4                | 0     | 2     | 10    | 9     | 6     | 2     | 29    |
| 5                | 3     | 38    | 33    | 18    | 2     | 3     | 97    |
| Usual Activity level |       |       |       |       |       |       |       |
| 1                | 6     | 25    | 38    | 14    | 9     | 1     | 93    |
| 2                | 0     | 11    | 16    | 19    | 0     | 0     | 46    |
| 3                | 1     | 9     | 23    | 10    | 3     | 1     | 47    |
| 4                | 3     | 17    | 10    | 13    | 4     | 2     | 49    |
| 5                | 1     | 20    | 21    | 10    | 3     | 2     | 57    |
| Pain/Discomfort level |       |       |       |       |       |       |       |
| 1                | 5     | 19    | 35    | 17    | 6     | 0     | 82    |
| 2                | 3     | 17    | 24    | 12    | 6     | 2     | 64    |
| 3                | 0     | 11    | 16    | 18    | 2     | 3     | 50    |
| 4                | 1     | 20    | 14    | 14    | 5     | 0     | 54    |
| 5                | 2     | 15    | 19    | 5     | 0     | 1     | 42    |
| Anxiety/Depression level |       |       |       |       |       |       |       |
| 1                | 6     | 18    | 28    | 21    | 3     | 1     | 77    |
| 2                | 1     | 12    | 23    | 11    | 4     | 1     | 52    |
| 3                | 1     | 18    | 21    | 13    | 5     | 2     | 60    |
| 4                | 3     | 21    | 12    | 14    | 5     | 1     | 56    |
| 5                | 0     | 13    | 24    | 7     | 2     | 1     | 47    |

MS - multiple sclerosis, EQ-5D - EuroQOL-5 Dimensions instrument
No significant difference was found between genders ($p=0.21$) (Figure 4). The histogram distribution of the numerical result EQ-VAS is shown in Figure 3. The correlation between the EQ-5D index and EQ-VAS was not significant ($r=0.019$, $p>0.005$) (Figure 5). However, we found out that age, sex, duration of illness, and treatment or on treatment have no significant association with the EQ-5D index value of quality of life among MS patients (Table 3).

Discussion. In this study, we elected to utilize the EQ-5D questionnaire due to its very simple format.
Dependent variable (EQ-5D index score)

| Independent Variables | Unstandardized coefficients B | Standardized coefficients B | P-value |
|-----------------------|-------------------------------|-----------------------------|---------|
| Age                   | .005                          | .090                        | .170    |
| Gender                | -.121                         | -.109                       | .064    |
| Duration of Illness in years | -.009                      | -.105                       | .107    |
| On treatment and not on treatment | .044                       | .052                        | .588    |

B - Beta, EQ-5D - EuroQOL-5 Dimensions instrument

Quality of life among MS Patients … Algahtani et al

Pain in MS patients is a common symptom estimated to affect more than 40% of patients. The pathophysiology explaining the pain in MS patients remains incompletely understood, but it is thought to be related to demyelinating lesions involving certain neuroanatomic pathways such as the spinothalamic and quintothalamic pathways, abnormal impulses through motor axons, development of an acquired channelopathy in affected nerves, or inflammatory immune mechanisms of the glial cell. Painful conditions in MS patients include central and peripheral neuropathy, trigeminal neuralgia, glossopharyngeal neuralgia, migraines, complex regional pain syndrome, painful tonic spasms, and transverse myelitis. MS relapses also cause pain, and patients usually report paroxysmal dystonia and neuropathic pain during the relapses. Pain is associated a reduced quality of life in patients with MS, and about 12% report pain as their worst symptom. In our patients, about 50% of the patients reported moderate to extreme problems with pain, which is close to other studies.

The use of disease modifying drugs has been reported to affect the quality of life. The variability of the results may be due to the availability of a variety of medications with variable side effects. The frequent self-injection with its associated side effects including injection-site reactions and flu-like symptoms may negatively impact the quality of life. Another important point to be illustrated is that the benefits of these medications may not be obvious to patients which may lead to low adherence and further relapses that will also affect the quality of life negatively. In our study, no statistically significant difference was found between the patients who were on disease modifying therapy compared to those who were not on disease modifying therapy. Although medications are supplied by the government for free since the hospitals are government supported, the reasons why patients refuse to take these medications remain to be studied. The use of newer medications with less injection frequency and oral medications may lead to improvements in the quality of life.

In our MS patients, quality of life showed an apparent propensity toward a decrease in mean results of EQ-5D and EQ-VAS with age. This observation most likely resulted as a consequence of increased disability throughout the course of the disease and occurrence of more symptoms of MS or other comorbidities that occur with age. Older patients with a progressive and long-term disease appraise their quality of life at a much lower level as compared to younger patients. This indicates that quality of life is mainly influenced by the disability level and disease duration. Our sample was a young one, and future research might capture and compare the same information in an older population.

www.neurosciencesjournal.org

Neurosciences 2017; Vol. 22 (4) 265
In conclusion, MS is a disease that is associated with a considerable effect on the patients quality of life. It continues to be challenging to manage both medically and psychosocially. We emphasize the importance of the assessment of quality of life in MS patients. Our results provided insight into a number of associations between patient variables and their quality of life. Healthcare providers should be aware of the low quality of life among patients to improve their quality of life. Clinicians should consider the assessment of quality of life as routine practice along with the other important measures including symptomatic evaluation, laboratory tests, and neuroimaging to provide a holistic care of their MS patients. The results of this study will help in emphasizing the importance of establishing specialized MS clinics, multidisciplinary caring team, and support groups which are currently few in number and limited to big cities.

References

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 2017; 13: 25-36.
3. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006; 108: 327-332.
4. Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun 2014; 48-49: 134-142.
5. Mitosek-szewczyk K, Kułakowska A, Bartosik-pszuk H, Hożejowski R, Drozdowski W, Stelmasiak Z. Quality of life in Polish patients with multiple sclerosis. Adv Med Sci 2014; 59: 34-38.
6. Aburuz S, Bulatova N, Twalbeh M, Gazawi M. The validity and reliability of the Arabic version of the EQ-5D: a study from Jordan. Ann Saudi Med 2009; 29: 304-308.
7. Reenen MV, Janssen B, editors. EQ-5D-5L User Guide Basic information on how to use the EQ-5D-5L instrument. The Netherlands: EuroQol Research Foundation; 2015. Available at: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf
8. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012; 15: 708-715.
9. Al-Tahan AM, Al-Jumah MA, Bohlega SM, Al-Shammari SN, Al-Sharoqi IA, Dahdaleh MP, et al. The importance of quality-of-life assessment in the management of patients with multiple sclerosis. Recommendations from the Middle East MS Advisory Group. Neurosciences (Riyadh) 2011; 16: 109-113.
10. Kes VB, Cengić L, Cesari M, Tomas AJ, Zavoroco I, Matovina LZ, et al. Quality of life in patients with multiple sclerosis. Acta Clin Croat 2013; 52: 107-111.
11. Göksele karatepe A, Kayı T, Günaydn R, Demirhan A, Ce P, Gedizlioglu M. Quality of life in patients with multiple sclerosis: the impact of depression, fatigue, and disability. Int J Rehabil Res 2011; 34: 290-298.
12. Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P. Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge. Mult Scler Int 2013; 2013: 524894.
13. Chen K, Fan Y, Hu R, Yang T, Li K. Impact of depression, fatigue and disability on quality of life in Chinese patients with multiple sclerosis. Stress Health 2013; 29: 108-112.
14. Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol 2013; 260: 351-367.
15. Nick ST, Roberts C, Billiodaux S, Davis DE, Zamanifekri B, Sahaian MA, et al. Multiple sclerosis and pain. Neurol Res 2012; 34: 829-841.
16. Kenner M, Menon U, Elliott DG. Multiple sclerosis as a painful disease. Int Rev Neurobiol 2007; 79: 303-321.
17. Lily O, Mfadden E, Hensor E, Johnson M, Ford H. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler 2006; 12: 808-813.

COPYRIGHT

Whenever a manuscript contains material (tables, figures, etc.) which is protected by copyright (previously published), it is the obligation of the author to obtain written permission from the holder of the copyright (usually the publisher) to reproduce the material in Neurosciences. This also applies if the material is the authors own work. Please submit copies of the material from the source in which it was first published.